Having made the streets safe for Truth, Justice, and Krispy Kreme donuts, he now patrols the markets looking for companies he can lock up as long-term holdings in a portfolio.
Since at least the 1920s, the tide of history proves that if you want to accumulate vast amounts of wealth, investing in stocks is the way to go.
Marijuana investors should be similarly rewarded for their patience if they buy into top cannabis companies and then hold onto them for decades.
territories, and cannabis-focused analytics firm BDSA projects annual pot sales will double between 2021 and 2026, hitting $48 billion.
Launched in 2016, Innovative Industrial Properties that specializes in the medical marijuana field.
That’s important for investors because it ensures the REIT will have a steady stream of revenue well into the next decade, and very likely well beyond.
Until legalization is passed at the federal level, the REIT is ensured of having a ready list of customers willing to participate in the program to access financing.
As REIT, Innovative Industrial is obligated to return 90% of its profits back to its shareholders and has quadrupled its dividend since going public.
It has 26 operating dispensaries, mostly in those states, but it can open an additional 10 retail locations across a handful of states based on the license approvals it has available.
What these states have in common is they’re largely limited license states, or places where either state or local governments limit the number of operators that can legally be in business, or the number of licenses an operator can hold.
That government-enforced restriction on competition, however, will allow Jushi to develop a loyal customer following and build up its brands, such as The Lab and Tasteology.
In the second quarter, which ended June 30, Jushi posted 15% revenue growth to almost $48 million, 78% of which was made online.
It recently secured a $100 million secured credit facility from SunStream Bancorp, a joint venture sponsored by Sundial Growers, and plans to use $40 million of the proceeds to fund a portion of its recent acquisition of Nature’s Remedy of Massachusetts.
Wall Street, though, forecasts the MSO will more than double revenue by 2023, to $520 million, and then increase it another 75% to $914 million one year later.